Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.

Autor: Taprogge J; National Radiotherapy Trials Quality Assurance (RTTQA) Group, Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK. jan.taprogge@icr.ac.uk.; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK. jan.taprogge@icr.ac.uk., Vergara-Gil A; Centre de Recherches en Cancérologie de Toulouse, UMR 1037, INSERM Université Paul Sabatier, Toulouse, France., Leek F; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.; Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK., Abreu C; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.; Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK., Vávrová L; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.; Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK., Carnegie-Peake L; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.; Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK., Schumann S; Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany., Eberlein U; Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany., Lassmann M; Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany., Schurrat T; Department of Nuclear Medicine, Philipps-University Marburg, Baldingerstrasse, 35043, Marburg, Germany., Luster M; Department of Nuclear Medicine, Philipps-University Marburg, Baldingerstrasse, 35043, Marburg, Germany., Verburg FA; Department of Nuclear Medicine, Philipps-University Marburg, Baldingerstrasse, 35043, Marburg, Germany.; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, Netherlands., Vallot D; IUCT Oncopole, Av. Irène Joliot-Curie, 31100, Toulouse, France., Vija L; IUCT Oncopole, Av. Irène Joliot-Curie, 31100, Toulouse, France., Courbon F; IUCT Oncopole, Av. Irène Joliot-Curie, 31100, Toulouse, France., Newbold K; Thyroid Unit, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK., Bardiès M; Centre de Recherches en Cancérologie de Toulouse, UMR 1037, INSERM Université Paul Sabatier, Toulouse, France.; Institut de Recherches en Cancérologie de Montpellier, UMR 1194, INSERM Université de Montpellier, 34298, Montpellier, France., Flux G; The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.; Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton, SM2 5PT, UK.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Sep; Vol. 50 (11), pp. 3225-3234. Date of Electronic Publication: 2023 Jun 10.
DOI: 10.1007/s00259-023-06295-0
Abstrakt: Purpose: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[ 131 I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[ 131 I]I.
Methods: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[ 131 I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated.
Results: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively.
Conclusions: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[ 131 I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje